Literature DB >> 16234822

Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.

K Rapp1, J Schroeder, J Klenk, S Stoehr, H Ulmer, H Concin, G Diem, W Oberaigner, S K Weiland.   

Abstract

We investigated the relation of overweight and obesity with cancer in a population-based cohort of more than 145 000 Austrian adults over an average of 9.9 years. Incident cancers (n=6241) were identified through the state cancer registry. Using Cox proportional-hazards models adjusted for smoking and occupation, increases in relative body weight in men were associated with colon cancer (hazard rate (HR) ratio 2.48; 95% confidence interval (CI): 1.15, 5.39 for body mass index (BMI) > or =35 kg m(-2)) and pancreatic cancer (HR 2.34, 95% CI: 1.17, 4.66 for BMI>30 kg m(-2)) compared to participants with normal weight (BMI 18.5-24.9 kg m(-2)). In women, there was a weak positive association between increasing BMI and all cancers combined, and strong associations with non-Hodgkin's lymphomas (HR 2.86, 95% CI: 1.49, 5.49 for BMI> or =30 kg m(-2)) and cancers of the uterine corpus (HR 3.93, 95% CI: 2.35, 6.56 for BMI> or =35 kg m(-2)). Incidence of breast cancer was positively associated with high BMI only after age 65 years. These findings provide further evidence that overweight is associated with the incidence of several types of cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16234822      PMCID: PMC2361672          DOI: 10.1038/sj.bjc.6602819

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


Overweight and obesity is an increasing health problem, not only for industrialised countries but also for most other parts of the world. This epidemic appears to be affecting all ages, including childhood (WHO, 2000). Prospective studies have observed an association between overweight and overall mortality (Lew and Garfinkel, 1979; Manson ; Calle ), and several adverse health consequences of elevated body weight are well established, including type II diabetes, hypertension and coronary heart disease (Must ). Obesity has also been associated with cancer incidence and mortality, and positive associations between obesity and risks of specific cancers, including endometrial and kidney cancer, are widely accepted (Calle and Kaaks, 2004). Inconsistent evidence of associations between other cancers and body weight may be due in part to small sample sizes and misclassification of body weight in retrospective studies. The relation between body mass index (BMI) and incidence of different cancers as ascertained by population-based cancer registries has been investigated by few studies (Moller ; Wolk ). We conducted a prospective investigation of the association between overweight and the incidence of cancer (overall and specific types) using data from the Vorarlberg cancer registry and a population-based cohort of more than 145 000 Austrian men and women followed for an average of nearly 10 years.

MATERIALS AND METHODS

Study population

The Vorarlberg Health Monitoring and Promotion Program (VHM&PP) is carried out in Vorarlberg, the westernmost province of Austria. It is performed routinely by the Agency of Social and Preventive Medicine and covers all adults of the whole province. The screening examination takes place in the practice of local physicians; it includes a physical examination, a blood test and a consultation with a doctor. Enrolment is voluntary and costs are covered by the participant's (compulsory) health insurance. More than two-thirds of the adult population of the province (between the age of 35 and 54 years) participated and underwent at least one examination since the beginning of the programme in 1985 (Ulmer ). The VHM&PP has been described in detail previously (Ulmer ). Between 1985 and 2001, 167 371 adult Vorarlberg residents were enrolled in the VHM&PP Study Cohort after signing an informed consent to store and process personal data (height, weight, smoking and other factors). The current analysis was restricted to participants with complete data on height, weight and occupational group at enrolment. As in a previous study (Calle ), participants with a baseline BMI (kg m−2) below normal (BMI<18.5 kg m−2, n=5053) were excluded. In order to avoid an influence of cancer growth on body weight, participants were further excluded if they had been diagnosed with a malignant cancer prior to enrolment, or within 1 year following enrolment (n=1831). Therefore, the first year of follow-up time was not considered in the analysis and participants with a follow-up period of less than 1 year (n=5528) were excluded. To evaluate the sensitivity of our analyses to this 1-year exclusion, we also repeated the analyses with a 3-year exclusion. The final study cohort consisted of 67 447 men and 78 484 women, with mean age at study entry of 41.8 years for men and 42.5 years for women (Table 1). The average time of follow-up was nearly 10 years, with a total of 1.45 million person-years. By the end of the total observation period of 17 years, 6241 incident cancers (other than nonmelanoma skin cancer) had been diagnosed (Table 1).
Table 1

Characteristics of the VHM&PP study cohort

  Men Women All
Eligible VHM&PP participants (N)a67 44778 484145 931
    
Age at entry (years)
 Mean (s.d.b)41.78 (14.47)42.48 (15.66)42.16 (15.12)
 Range18.66–93.0319.00–94.1318.66–94.13
    
Years of follow-up
 Mean (s.d.b)9.63 (4.63)10.18 (4.56)9.93 (4.60)
 Range0.00–16.890.00–16.840.00–16.89
 Total person-years at risk649 358799 1221 448 480
    
BMIc (%)
 Normal: 18.5–24.9 kg m−250.4762.8657.13
 Overweight: 25–29.9 kg m−240.0525.6032.28
 Obese I: 30–34.9 kg m−28.238.558.40
 Obese II and III: ⩾35 kg m−21.252.992.19
    
Smoking (%)
 Current smoker29.9920.7825.03
 Former smoker13.274.998.79
    
Occupational groupd (%)
 Blue collar37.2938.0937.72
 White collar51.9954.0853.12
 Self-employed10.727.829.16
    
Number of cancers333729046241
    
Age at cancer diagnosis (years)
 Mean (s.d.b)65.34 (11.49)62.88 (13.21)64.20 (12.38)
 Range22.87–95.6922.43–96.2922.43–96.29

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; BMI=body mass index.

Eligible participants were enrolled between 1985 and 2001, had complete baseline data for BMI, smoking and occupational group, and had no history of malignant cancer prior to or within 1 year after baseline. Participants with nonmelanoma skin cancer were excluded.

s.d.: standard deviation.

BMI: body mass index (kg m−2) based on height and weight measured at baseline physical examination.

Occupational group classified according to insurance number for occupation at baseline, prior occupation (for pensioners) or husband's occupation (for housewives).

Body mass index

Baseline height and weight were recorded by medical staff at enrolment during the VHM&PP physical examination. BMI was classified according to World Health Organisation guidelines as normal (18.50–24.99 kg m−2), overweight (25.00–29.99 kg m−2), obese class I (30.00–34.99 kg m−2), and obese class II and III (⩾35.00 kg m−2) (2000). Normal BMI was the reference category for all analyses, and obesity categories were combined when necessary to ensure a minimum of five cancer outcomes in each exposure group.

Covariates

Associations were adjusted for smoking by including variables for current smoking and former smoking in the model, with the reference group being never smokers. Persons with missing smoking values were classified as never smokers because baseline questionnaire data did not differentiate between never-smokers and participants with missing values. However, smoking information from follow-up visits was available to validate the baseline smoking status of more than 70% of study participants. Occupational group (blue collar, white collar or self-employed) was determined by the insurance number of participants and was included in the models as a surrogate measure of socioeconomic status. Participants who were retired at baseline were classified according to their former occupation, and housewives according to their husband's occupation.

End points

Between 1985 and 2002, incident invasive cancers were identified by the Vorarlberg cancer registry, which is accepted for publication by the International Agency for Research on Cancer (IARC) since 1993 (Parkin ). The proportion of cancers discovered by death certificate only (DCO) in the Vorarlberg registry for cases diagnosed between 1993 and 1997 was 7% for men and 9% for women (Oberaigner ), and for cases diagnosed between 1998 and 2002 about 5% in both sexes (W Oberaigner, personal communication, Cancer Registry of Tyrol). Nearly all cancers were histologically verified and coded according to the ninth revision of the International Classification of Diseases (ICD-9). Cohort data were linked with the Vorarlberg Death Index to identify deaths among cohort members to calculate person-years at risk.

Statistical analysis

We used Cox proportional-hazards models to compute hazard rate ratios (HR) and 95% confidence intervals (95% CI) for overweight and obesity relative to normal BMI, adjusted for smoking and occupational group at baseline. The models included age (in single years) in the strata statement. In tests of linear trend by BMI, the median value for BMI within each interval was entered in a regression model, and the significance of the term tested by the Wald's χ2 test. All calculations were carried out with SAS version 8.2 software. All analyses were performed separately for men and women. Analyses on specific cancers were restricted to those types of cancer with at least 50 cases in men or women.

RESULTS

The study cohort consisted of 67 447 men and 78 484 women (Table 1). In men, positive linear trends in cancer incidence with increasing BMI were observed for colon and pancreatic cancer (Table 2). In comparison to men with normal weight, the hazard ratios for colon cancer were 1.56 (95% CI: 1.06, 2.30) for men with BMI 30.0–34.99 kg m−2, and 2.48 (1.15, 5.39) for BMI 35.0 kg m−2 or more. The hazard ratios for men with BMI of at least 30.0 kg m−2 were for rectal cancer 1.66 (1.00, 2.73) and for pancreatic cancer 2.34 (1.17, 4.66). Nonsignificant positive associations were found for kidney and liver cancers.
Table 2

Estimated HR and 95% CI for incident cancers diagnosed among male participants in the VHM&PP Study Cohort 1985–2001, according to BMI at enrolment

  BMI (kg m−2)a  
  18.5–24.9 25–29.9 30–34.9 ⩾35  
Type of cancer Normal Overweight Obese I Obese II and III  
Number of persons/pyb 34 040/330 040 27 012/262 144 5552/50 385 843/6788 P for trend
All cancers
 Incident cases/pyb1364/10 2931591/12 078342/245940/259 
 HR (95% CI)c1.000.97 (0.91–1.05)0.96 (0.85–1.08)0.94 (0.69–1.29)0.37
      
Stomach cancer (ICD-9 151)
 Incident cases/pyb58/40075/54613/67  
 HR (95% CI)c1.001.04 (0.73–1.47)0.72a (0.40–1.33) 0.44
      
Colon cancer (ICD-9 153)
 Incident cases/pyb86/663128/94239/2757/44 
 HR (95% CI)c1.001.14 (0.86–1.50)1.56 (1.06–2.30)2.48 (1.15–5.39)0.005
      
Rectal cancer (ICD-9 154)
 Incident cases/pyb45/32769/49924/163  
 HR (95% CI)c1.001.20 (0.82–1.75)1.66a (1.01–2.73) 0.053
      
Liver cancer (ICD-9 155)
 Incident cases/pyb18/12829/19710/92  
 HR (95% CI)c1.001.32 (0.73–2.37)1.67a (0.75–3.72) 0.19
      
Pancreatic cancer (ICD-9 157)
 Incident cases/pb19/12931/25014/109  
 HR (95% CI)c1.001.29 (0.73–2.27)2.34a (1.17–4.66) 0.02
      
Lung cancer (ICD-9 162)
 Incident cases/pyb209/1427198/128850/3087/32 
 HR (95% CI)c1.000.80 (0.66–0.97)0.88 (0.65–1.20)0.88 (0.41–1.86)0.15
      
Melanoma (ICD-9 172)
 Incident cases/pyb59/37356/4097/48  
 HR (95% CI)c1.001.00 (0.68–1.46)0.59a (0.27–1.31) 0.32
      
Prostate cancer (ICD-9 185)
 Incident cases446/4001583/516599/76610/88 
 HR (95% CI)c1.001.03 (0.91–1.17)0.82 (0.66–1.03)0.73 (0.39–1.37)0.16
      
Bladder cancer (ICD-9 188)
 Incident cases/pyb78/52278/50719/136  
 HR (95% CI)c1.000.81 (0.59–1.11)0.74a (0.45–1.22) 0.15
      
Kidney cancer (ICD-9 189)
 Incident cases/pyb46/35670/48621/162  
 HR (95% CI)c1.001.19 (0.82–1.74)1.46a (0.87–2.46) 0.14
      
Non-Hodgkin's lymphoma (ICD-9 200+202)
 Incident cases/pyb31/23645/2888/54  
 HR (95% CI)c1.001.26 (0.80–2.01)0.91a (0.41–1.99) 0.86

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; HR=hazards ratio; CI=confidence interval; ICD=International Classification of Diseases; BMI=body mass index.

Obese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.

Person-years.

The Cox proportional-hazards model was stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.

In women, there was a weak positive association between BMI and all cancers (Table 3). Endometrial (uterine corpus) cancer was strongly associated with obesity class I (hazard ratio 2.13 (1.38, 3.27)) and obesity class II and III (hazard ratio 3.93 (2.35, 6.56)) in comparison to normal weight. Furthermore, a positive association was found between obesity and the incidence of non-Hodgkin's lymphomas (NHL) (hazard ratio 2.86 (1.49, 5.49), with a BMI of at least 30.0 kg m−2). Kidney cancer was associated with overweight, though not statistically significant. In contrast to men, BMI was not associated with colon or rectal cancer in women.
Table 3

Estimated HR and 95% CI for incident cancers diagnosed among female participants in the VHM&PP Study Cohort 1985–2001, according to BMI at enrolment

  BMI (kg m−2)a
 
Type of cancer 18.5–24.9 25–29.9 30–34.9 ⩾35  
Number of persons/pyb 49 336/502 849 20 090/208 574 6709/66 351 2349/21 349 P for trend
All cancers
 Incident cases/pyb1425/10 712997/6883369/2493113/795 
 HR (95% CI)c1.001.05 (0.96–1.14)1.16 (1.03–1.30)1.18 (0.97–1.43)0.008
      
Stomach cancer (ICD-9 151)
 Incident cases/pyb56/39436/21220/1466/45 
 HR (95% CI)c1.000.78 (0.51–1.20)1.28 (0.76–2.15)1.34 (0.57–3.13)0.48
      
Colon cancer (ICD-9 153)
 Incident cases/pyb122/958106/77335/2388/82 
 HR (95% CI)c1.001.13 (0.86–1.47)1.11 (0.76–1.62)0.88 (0.43–1.81)0.73
      
Rectal cancer (ICD-9 154)
 Incident cases/pyb68/50448/31512/1005/27 
 HR (95% CI)c1.000.90 (0.62–1.31)0.66 (0.36–1.23)0.96 (0.38–2.39)0.32
      
Pancreatic cancer (ICD-9 157)
 Incident cases/pyb29/23121/15415/80  
 HR (95% CI)c1.000.87 (0.49–1.53)1.42a (0.76–2.68) 0.4
      
Lung cancer (ICD-9 162)
 Incident cases/pyb64/51345/30017/97  
 HR (95% CI)c1.001.00 (0.68–1.48)0.87a (0.50–1.50) 0.67
      
Melanoma (ICD-9 172)
 Incident cases/pyb79/53538/26813/77  
 HR (95% CI)c1.001.03 (0.68–1.54)0.86a (0.47–1.57) 0.72
      
Breast cancer (ICD-9 174)
 Incident cases/pyb551/4162335/2326123/86036/270 
 HR (95% CI)c1.000.96 (0.83–1.10)1.07 (0.88–1.31)1.01 (0.72–1.42)0.8
      
Cervical cancer (ICD-9 180)
 Incident cases/pyb41/20517/1066/43  
 HR (95% CI)c1.000.85 (0.47–1.54)0.69a (0.29–1.66) 0.37
      
Cancer of the uterine corpus (ICD-9 182)
 Incident cases/pyb63/45259/44133/23020/93 
 HR (95% CI)c1.001.29 (0.90–1.86)2.13 (1.38–3.27)3.93 (2.35–6.56)<0.001
      
Ovarian cancer (ICD-9 183)
 Incident cases/pyb61/49039/24521/141  
 HR (95% CI)c1.001.03 (0.68–1.56)1.25a (0.75–2.08) 0.44
      
Bladder cancer (ICD-9 188)
 Incident cases/pyb21/12822/12011/85  
 HR (95% CI)c1.001.35 (0.74–2.48)1.60a (0.76–3.36) 0.19
      
Kidney cancer (ICD-9 189)
 Incident cases/pyb32/29044/29912/77  
 HR (95% CI)c1.001.81 (1.13–2.89)1.14a (0.58–2.24) 0.3
      
Thyroid cancer (ICD-9 193)
 Incident cases/pyb29/17324/1838/52  
 HR (95% CI)c1.001.45 (0.82–2.58)1.18a (0.53–2.65) 0.44
      
Non-Hodgkin's lymphoma (ICD-9 200+202)
 Incident cases/pyb22/15424/17018/126  
 HR (95% CI)c1.001.64 (0.89–3.01)2.86a (1.49–5.49) 0.002

VHM&PP=Vorarlberg Health Monitoring and Promotion Program; HR=hazards ratio; CI=confidence interval; ICD=International Classification of Diseases; BMI=body mass index.

Obese categories (class I and class II and III) were combined as needed to ensure at least five cases in each.

Person-years.

The Cox proportional-hazards model was stratified according to age at enrolment (in years) and adjusted for smoking status and occupational group.

There was little evidence of an association between breast cancer and BMI overall. However, breast cancer diagnosed in women aged 65 years or older was positively associated with BMI (hazard ratios 1.48 (1.12, 1.95) for obesity class I and 1.29 (0.79, 2.11) for obesity class II and III; P for trend 0.02). All associations that were statistically significant after exclusion of the first year following entry into the study remained unchanged in terms of statistical significance when reanalysed excluding the first 3 years.

DISCUSSION

The major strengths of our study are the prospective design, the large number of subjects, the coverage of incident cases and the length of follow-up. The population of Vorarlberg is culturally and ethnically rather homogenous, with more than 90% of Austrian origin (Ulmer ). Body mass index was based on height and weight measured at initial physical examination. Incident cancers were ascertained by the population-based cancer registry and nearly all histologically confirmed; the likelihood of exposure and outcome misclassification was therefore low. The limitations of our study include that, despite the overall size of the cohort, some cancers of interest (for example, oesophageal adenocarcinoma or gallbladder cancer) could not be evaluated due to small numbers of cases. In addition, the prevalence of obesity in our cohort was relatively low. Consequently the power to examine extreme levels of obesity, particularly in association with less common cancers, was limited. The high proportion of never-smoking patients with lung cancer (31%) suggests that there was some misclassification of smoking status, although this would probably attenuate the relation between BMI and most cancers, given the inverse association between smoking and body weight. We used occupational group as a rough surrogate for socioeconomic status, but were unable to account for such potentially confounding factors as alcohol consumption or physical activity. Our finding of an association between BMI and both colon and rectum cancers in men supports earlier observations (Lew and Garfinkel, 1979; Giovannucci ; Pan ; Samanic ) and may be due to the growth-promoting effects of insulin and insulin-like growth factor (IGF-1), both increased in obesity (Calle and Kaaks, 2004). Our failure to find an association between BMI and colon cancer in women also agrees with other studies (Phillips and Snowdon, 1985; Shimizu ), and may be related to the protective effects of elevated oestrogen levels in overweight postmenopausal women, as found by studies of exogenous hormone therapy in such women (Calle ; Newcomb and Storer, 1995). We observed a positive association between pancreatic cancer and overweight or obesity in men, and to a lesser extent in women. Other studies have been inconsistent in this connection (Berrington ). As with colon cancer, relations between pancreatic cancer and BMI have been attributed to the growth-promoting effects of elevated insulin and IGFs secondary to obesity (Takeda and Escribano, 1991), although the carcinogenic effects of insulin have also been proposed to explain positive associations with abnormal glucose metabolism (Gapstur ) or diabetes mellitus (Everhart and Wright, 1995). In line with previous reports (Yuan ; Chow ), we observed a positive relation between BMI and incidence of kidney cancer in men, which, however, did not reach statistical significance. In women, our findings showed a positive association between kidney cancer and overweight, but not obesity. Our finding of a positive association between BMI and breast cancer only among women at the age of 65 years or older is consistent with previous reports (Hunter and Willett, 1993). A relation between endometrial cancer (cancer of the uterine corpus) and overweight is widely accepted (Calle and Kaaks, 2004), and it was found that this in very obese women (BMI⩾35 kg m−2) were more likely to be diagnosed with endometrial cancer than women with normal BMI at baseline (HR 3.93, 95% CI: 2.35, 6.56). A crucial pathway seems to be oestrogens that are not counterbalanced by progesterone (the ‘unopposed oestrogen’ hypothesis) (Kaaks ). Anovulatory cycles in obese premenopausal women may contribute to a deficiency of progesterone, which normally opposes the mitogenic effect of oestrogen on the endometrial mucosa. We also observed a strong positive association between BMI and NHL among women, but not men. Previous prospective studies of overweight and NHL have been inconsistent (Moller ; Wolk ; Cerhan ; Calle ; Samanic ), though several case–control studies have reported an association between overweight and NHL in both sexes (Holly ; Pan ; Skibola ). The incidence of NHL has increased in many parts of the world (Muller ) and obesity might be a contributing factor. As previously reported (Calle and Kaaks, 2004), liver cancer showed a (non-significant) association with BMI in men with point estimates clearly above one, but based on only 57 cases; there were too few cases of liver cancer for a separate analysis in women. Many studies have examined relations between overweight and single cancer outcomes. Few prospective studies examined the influence of overweight on a range of specific cancers both in men and women (Lew and Garfinkel, 1979; Moller ; Wolk ; Calle ). Our study of a large Austrian cohort provides additional support from another population for associations between BMI and the incidence of colon, rectal and pancreatic cancer, and to a lesser extent of kidney and liver cancer in men, and with endometrial cancer, postmenopausal breast cancer and NHL in women.
  30 in total

Review 1.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.

Authors:  Eugenia E Calle; Rudolf Kaaks
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

2.  Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines.

Authors:  Y Takeda; M J Escribano
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  Diet, body size, and breast cancer.

Authors:  D J Hunter; W C Willett
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

4.  Obesity and cancer risk: a Danish record-linkage study.

Authors:  H Møller; A Mellemgaard; K Lindvig; J H Olsen
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

5.  Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality.

Authors:  Hanno Ulmer; Cecily Kelleher; Günter Diem; Hans Concin
Journal:  J Womens Health (Larchmt)       Date:  2004 Jan-Feb       Impact factor: 2.681

6.  Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: the Vorarlberg Health Monitoring & Promotion Programme.

Authors:  Hanno Ulmer; Cecily Kelleher; Günter Diem; Hans Concin
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

7.  Dietary relationships with fatal colorectal cancer among Seventh-Day Adventists.

Authors:  R L Phillips; D A Snowdon
Journal:  J Natl Cancer Inst       Date:  1985-02       Impact factor: 13.506

8.  Association of obesity and cancer risk in Canada.

Authors:  Sai Yi Pan; Kenneth C Johnson; Anne-Marie Ugnat; Shi Wu Wen; Yang Mao
Journal:  Am J Epidemiol       Date:  2004-02-01       Impact factor: 4.897

9.  Variations in mortality by weight among 750,000 men and women.

Authors:  E A Lew; L Garfinkel
Journal:  J Chronic Dis       Date:  1979

10.  Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma.

Authors:  Christine F Skibola; Elizabeth A Holly; Matthew S Forrest; Alan Hubbard; Paige M Bracci; Danica R Skibola; Christine Hegedus; Martyn T Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-05       Impact factor: 4.254

View more
  95 in total

1.  Body mass index, agricultural pesticide use, and cancer incidence in the Agricultural Health Study cohort.

Authors:  Gabriella Andreotti; Lifang Hou; Laura E Beane Freeman; Rajeev Mahajan; Stella Koutros; Joseph Coble; Jay Lubin; Aaron Blair; Jane A Hoppin; Michael Alavanja
Journal:  Cancer Causes Control       Date:  2010-08-22       Impact factor: 2.506

2.  Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

3.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

4.  Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.

Authors:  Yao-Ping Lu; Bonnie Nolan; You-Rong Lou; Qing-Yun Peng; George C Wagner; Allan H Conney
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

5.  A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.

Authors:  Bincy Philip; Christina L Roland; Jaroslaw Daniluk; Yan Liu; Deyali Chatterjee; Sobeyda B Gomez; Baoan Ji; Haojie Huang; Huamin Wang; Jason B Fleming; Craig D Logsdon; Zobeida Cruz-Monserrate
Journal:  Gastroenterology       Date:  2013-08-16       Impact factor: 22.682

6.  The occurrence of fetal microchimeric cells in endometrial tissues is a very common phenomenon in benign uterine disorders, and the lower prevalence of fetal microchimerism is associated with better uterine cancer prognoses.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Petra Pirkova; Pavla Libalova; Zdenka Vernerova; Bohuslav Svoboda; Eduard Kucera
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

Review 7.  Incidence of cancer following bariatric surgery: systematic review and meta-analysis.

Authors:  Daniela Schaan Casagrande; Daniela Dornelles Rosa; Daniel Umpierre; Roberta Aguiar Sarmento; Clarissa Garcia Rodrigues; Beatriz D Schaan
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

8.  Cancer incidence and mortality after gastric bypass surgery.

Authors:  Ted D Adams; Antoinette M Stroup; Richard E Gress; Kenneth F Adams; Eugenia E Calle; Sherman C Smith; R Chad Halverson; Steven C Simper; Paul N Hopkins; Steven C Hunt
Journal:  Obesity (Silver Spring)       Date:  2009-01-15       Impact factor: 5.002

Review 9.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

10.  Generational risks for cancers not related to tobacco, screening, or treatment in the United States.

Authors:  Yueh-Ying Han; Devra L Davis; Joel L Weissfeld; Gregg E Dinse
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.